Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Jefferies Downgrades CytomX Therapeutics to Hold, Lowers Price Target to $2

Jefferies analyst Roger Song downgrades CytomX Therapeutics (NASDAQ:CTMX) from Buy to Hold and lowers the price target from $12 to $2.

July 7, 2022

1 minute read

Jefferies analyst Roger Song downgrades CytomX Therapeutics (NASDAQ:CTMX) from Buy to Hold and lowers the price target from $12 to $2.

Peloton Interactive Unveils Peloton Tread With Enhanced Safety Measures

August 24, 2:39 PM

Peloton Interactive Inc’s (NASDAQ:PTON) Peloton Tread will be available in the U.S., Canada, and the U.K. from August 30 and Germany…

February 22, 6:46 AM

Needham analyst Quinn Bolton initiates coverage on Credo Technology Group (NASDAQ:CRDO) with a Buy rating and announces Price Target of $20.

October 8, 9:03 AM

Jefferies analyst Michael Yee maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $500 to $400.

July 30, 12:27 PM

Morgan Stanley maintains 2U (NASDAQ:TWOU) with a Equal-Weight and raises the price target from $53 to $55.